Boston Scientific Q3 Earnings Call Highlights

Boston Scientific (BSX) reported Q3 adjusted gross margin at 68.0%, down 300 basis points YoY. It forecasts 2026 organic revenue growth of 3.75%, adjusted EPS of $3.16-$3.18, and $3.6B in free cash flow. Challenges in EP and WATCHMAN businesses are expected to persist into 2027, with recovery anticipated in 2028. A restructuring program aims to generate $500M in savings over three years.

Original reporting
Published Oct 29, 2026, 6:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 6:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Boston Scientific Q3 Earnings Call Highlights — source image
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The guidance signals slower growth and operational challenges, likely prompting a sell‑off or caution among traders.

02

Market read

First report of Boston Scientific's earnings and guidance, a primary earnings disclosure with material impact on the stock.

03

What to watch

New product launches (Nalu, AGENT balloon) and the Penumbra acquisition may offset near‑term headwinds.

Relevance 8/10Novelty 8/10Timing: today

Background

The article summarizes Boston Scientific's Q3 earnings call, providing detailed segment performance and FY2026 outlook.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific disclosed Q3 results and FY2026 guidance, including organic revenue growth of ~3.75% and adjusted EPS of $3.16‑$3.18.

Expected impact

likely downside as investors price in slower growth and 2027 pressure

Evidence & confidence

The new guidance is lower than prior expectations and flags operational challenges, which typically depress the stock.

Market effects

Medical device sector may see broader scrutiny on electrophysiology and left‑atrial closure markets.

U.S. healthcare stocks could face modest pressure in the short term.

Limited; impact confined to U.S. med‑tech equities.

Counterpoint

Restructuring savings of $500M could eventually boost margins, offering a longer‑term upside.

Key entities

  • Boston Scientific

    Medical device manufacturer reporting earnings and guidance.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.